COVID-19 Associated Imported Plasmodium vivax Malaria Relapse: First Reported Case and Literature Review
Author(s) -
Zubair Shahid,
Nadia Karim,
Fakhar Shahid,
Zohaib Yousaf
Publication year - 2021
Publication title -
research and reports in tropical medicine
Language(s) - English
Resource type - Journals
ISSN - 1179-7282
DOI - 10.2147/rrtm.s292157
Subject(s) - plasmodium vivax , malaria , headaches , virology , immunology , biology , chloroquine , medicine , plasmodium falciparum , psychiatry
Plasmodium vivax ( P. vivax ) is a protozoan parasite that causes vivax malaria. Disease relapse post-treatment is reported in P. vivax co-infection with other bacterial and parasitic infections, but Plasmodium vivax reactivation is not very common with viral infections. Early recognition and diagnosis of a Plasmodium vivax malaria relapse in a non-endemic region pose a diagnostic dilemma. COVID-19 co-infection compounds this dilemma due to overlapping symptoms. Early diagnosis and treatment are essential for a favorable clinical outcome. We report a middle-aged gentleman with high-grade fever and headaches who had COVID-19 and was found to have a relapse of Plasmodium vivax malaria.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom